<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Problems of Virology</journal-id><journal-title-group><journal-title xml:lang="en">Problems of Virology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы вирусологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0507-4088</issn><issn publication-format="electronic">2411-2097</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12264</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immunization with live attenuated A/H5N1 vaccine protects guinea pigs from reinfection</article-title><trans-title-group xml:lang="ru"><trans-title>Иммунизация живым аттенуированным вирусом гриппа A/H5N1 защищает морских свинок от реинфекции</trans-title></trans-title-group></title-group><pub-date date-type="pub" iso-8601-date="2013-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2013</year></pub-date><volume>58</volume><issue>6</issue><issue-title xml:lang="en">VOL 58, NO6 (2013)</issue-title><issue-title xml:lang="ru">ТОМ 58, №6 (2013)</issue-title><fpage>36</fpage><lpage>39</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Sergeeva M.V., Kuznetsov V.V., Kasianenko M.A., Shaldzhan A.A., Repko I.A., Potapchuk M.V., Romanova J.R., Tsybalova L.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Сергеева М.В., Кузнецов В.В., Касьяненко М.А., Шалджян А.А., Репко И.А., Потапчук М.В., Романова Ю.Р., Цыбалова Л.М.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Sergeeva M.V., Kuznetsov V.V., Kasianenko M.A., Shaldzhan A.A., Repko I.A., Potapchuk M.V., Romanova J.R., Tsybalova L.M.</copyright-holder><copyright-holder xml:lang="ru">Сергеева М.В., Кузнецов В.В., Касьяненко М.А., Шалджян А.А., Репко И.А., Потапчук М.В., Романова Ю.Р., Цыбалова Л.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://virusjour.crie.ru/jour/article/view/12264">https://virusjour.crie.ru/jour/article/view/12264</self-uri><abstract xml:lang="en"><p>Cold-adapted influenza virus A/HK/1/68/162/35(H3N2) was developed as unified donor of attenuation and high reproductive capacity for vaccine strains. the reassortant of this donor with surface antigens of highly pathogenic strain А/chicken/Astana/6/05 (H5N1) was tested in guinea pigs as a live or inactivated preparation. immunization with both formulations induced equal levels of serum virus specific antibodies, while the level of mucosal antibodies was significantly higher in animals immunized with live virus. the challenge with the homologous virus demonstrated complete virus clearance only in this group, thereby indicating a direct correlation of the protection level with the level of mucosal antibodies.</p></abstract><trans-abstract xml:lang="ru"><p>Холодоадаптированный вирус гриппа А/Гонконг/1/68/162/35 (H3N2) получен как универсальный донор аттенуации и репродуктивности для вакцинных и производственных штаммов. прототипы живых аттенуированных вакцин и инактивированных вакцин, подготовленные из реассортанта данного донора с поверхностными антигенами высокопатогенного вируса A/chicken/Astana/6/05 (H5N1), были изучены на морских свинках. Иммунизация обоими препаратами индуцировала одинаковый уровень сывороточных антител (АТ), однако уровень мукозальных АТ был значительно выше в группе животных, привитых живым вирусом. Только в этой группе отмечено полное подавление репродукции реинфицирующего вируса, что подтверждает наличие прямой зависимости защищенности от уровня местных АТ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>inactivated vaccine</kwd><kwd>live vaccine</kwd><kwd>Influenza H5N1</kwd><kwd>guinea pigs</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>инактивированная вакцина</kwd><kwd>живая вакцина</kwd><kwd>вирус гриппа H5N1</kwd><kwd>морские свинки</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Александрова Г.И., Климов А.И. Живая вакцина против гриппа. М.: Наука; 1994.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Потапчук М.В., Репко И. А., Сергеева М.В. и др. Характеристика реассортантных штаммов вируса гриппа на основе нового донора А/Гонконг/1/68/162/35(Н3№). Вопросы вирусологии. 2012; 57 (6): 42-6.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Цыбалова Л.М., Горев Н.Е., Потапчук М.В. и др. Характеристика холодоадаптированного штамма вируса гриппа А/ Гонконг/1/68/162/35 (H3N2) как потенциального донора аттенуации и высокой репродуктивности. Вопросы вирусологии. 2012; 57 (6): 13-7.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Beyer W.E., Palache A.M., de Jong J.C., Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine. 2002; 20: 1340-53.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004; 59: 1-15.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Harvey R., Wheeler J.X., Wallis C.L. et al. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low hemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine. 2008; 26: 6550-4.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Horimoto T., Takada A., Fujii K. et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine. 2006; 24: 3669-76.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kistner O., Howard M.K., Spruth M. et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine. 2007; 25: 6028-36.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lowen A.C., Steel J., Mubareka S. et al. Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J. Virol. 2009; 83: 2803-18.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Nurpeysova A., Khairullin B., Kassenov M. et al. Preclinical testing of Kazfluvac, a vaccine against pandemic influenza A/H5N1v. J. Pharm. Biomed. Sci. 2011; 1: 108-12.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Reed L.I., Muench H. A simple method of estimation fifty per cent endpoints. Am. J. Hyg. 1938; 27: 493-7.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Romanova J., Krenn B.M., Wolschek M. et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One. 2009; 4: e5984.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Rudenko L., Katlinsky A. Evaluation of Russian live attenuated vaccine H5N2 in clinical trials. http://www.who.int/entity/vaccine_research/diseases/influenza/160207_Rudenko.pdf (дата обращения 26.08.2012).</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Rudneva I.A., Sklyanskaya E.I., Barulina O.S. et al. Phenotypic expression of HA-NA combinations in human-avian influenza A reassortants. Arch. Virol. 1996; 141: 1091-9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rudneva I.A., Timofeeva T.A., Shilov A.A. et al. Effect of gene constellation and postreassortment amino acid change on the phenotypic features of H5 influenza virus reassortants. Arch. Virol. 2007; 152: 1139-45.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Stephenson I., Wood J.M., Nicholson K.G. et al. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004; 103: 91-5.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Sultankulova K.T., Sandybayev N.T., Chervyakova O.V. et al. New recombinant strain A/HK/Astana/6:2/2010 for prophylaxis of A/H5N1 influenza. BTRB. 2012; 1: 5-14.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Sun Y., Bi Y., Pu J. et al. Guinea pig model for evaluating the potential public health risk of swine and avian influenza viruses. PLoS One. 2010; 5: e15537.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Van Hoeven N., Belser J.A., Szretter K.J. et al. Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J. Virol. 2009; 83: 2851-61.</mixed-citation></ref></ref-list></back></article>
